格隆汇11月27日丨金石亚药(300434.SZ)在投资者互动平台表示，公司是国内感冒药一线产品"快 克"和"小快克"的品牌缔造者和拥有者。经过二十多年的品牌积累，已经成功搭建围绕成人及儿童感咳 领域的产品集群。其中，重点产品有"快克"复方氨酚烷胺胶囊适用于缓解普通感冒及流行性感冒的各种 症状，也可用于流行性感冒的预防和治疗；"小快克"小儿氨酚黄那敏颗粒适用于缓解儿童普通感冒及流 行性感冒引起的各种症状；"快克清"磷酸奥司他韦胶囊适用于成人和1岁及1岁以上儿童的甲型和乙型流 感治疗以及成人和13岁及13岁以上青少年的甲型和乙型流感的预防。此外，还有愈美甲麻敏糖浆、蒲地 蓝消炎片、抗病毒口服液、复方金银花颗粒、感冒清热颗粒、布洛伪麻片、枇杷止咳颗粒、布洛芬颗 粒、小儿咳喘灵颗粒、板蓝根颗粒等多个产品，满足消费者预防、缓解、治疗感冒的多方面需求。 ...

格隆汇11月27日丨金石亚药(300434.SZ)在投资者互动平台表示，公司是国内感冒药一线产品"快 克"和"小快克"的品牌缔造者和拥有者。经过二十多年的品牌积累，已经成功搭建围绕成人及儿童感咳 领域的产品集群。其中，重点产品有"快克"复方氨酚烷胺胶囊适用于缓解普通感冒及流行性感冒的各种 症状，也可用于流行性感冒的预防和治疗；"小快克"小儿氨酚黄那敏颗粒适用于缓解儿童普通感冒及流 行性感冒引起的各种症状；"快克清"磷酸奥司他韦胶囊适用于成人和1岁及1岁以上儿童的甲型和乙型流 感治疗以及成人和13岁及13岁以上青少年的甲型和乙型流感的预防。此外，还有愈美甲麻敏糖浆、蒲地 蓝消炎片、抗病毒口服液、复方金银花颗粒、感冒清热颗粒、布洛伪麻片、枇杷止咳颗粒、布洛芬颗 粒、小儿咳喘灵颗粒、板蓝根颗粒等多个产品，满足消费者预防、缓解、治疗感冒的多方面需求。 ...

Group 1: Company Strategy and Development - The company adheres to a dual strategy of independent and collaborative research and development, enhancing its long-term development through strategic investments and internal resource integration [1] - The company aims to become a trusted and preferred provider of professional healthcare products, focusing on a unified operational system across R&D, marketing, and production [2] - The company plans to implement a four-pronged growth model encompassing OTC, prescription drugs, traditional Chinese medicine, and health products to support high-quality development [2] Group 2: Marketing and Sales Achievements - The company has established a comprehensive marketing system, covering over 3,000 chain pharmacies and approximately 240,000 cooperative chain stores, reaching over 90% of cities and 70% of districts nationwide [2] - The company’s online channel strategy includes partnerships with e-commerce platforms to enhance product accessibility and consumer engagement [2] Group 3: Financial Performance - In 2024, the pharmaceutical segment generated revenue of 915 million yuan, accounting for 82.96% of total revenue, with the "Kuaike" series contributing 612 million yuan, representing 55.49% of total revenue [3] - The company’s cold and flu medications account for approximately 56% of total revenue [4] Group 4: Product Development and Market Position - The "Kuaike" cold medicine has ranked first in the annual comprehensive statistics of non-prescription drugs in China for three consecutive years from 2021 to 2023 [3] - The company has successfully launched the "Kuaike Qing" oseltamivir capsules and has received re-listing permits for other products [1] Group 5: Future Plans and Challenges - The company is actively preparing for the flu season by optimizing production capacity and ensuring smooth supply channels [5] - The company is exploring opportunities in traditional Chinese medicine, developing high-quality products to enhance market share in this sector [5]